Physician profile
John P Agent
NPI 1649217191
$1,395.92
in general payments reported to CMS, 2019-2025
21 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $155 · 2021: $196 · 2022: $212 · 2023: $288 · 2024: $136 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $596 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $596.42 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $299.56 | 2021-2024 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $217.87 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $118.66 | 2019-2025 | Airsupra, Breztri |
| Amgen INC. | $98.04 | 2019-2023 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $92.80 | 2019-2024 | Trelegy Ellipta |
| Pfizer INC. | $68.85 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $66.32 | 2020-2021 | |
| Amarin Pharma, INC. | $51.42 | 2020 | |
| Exact Sciences Corporation | $51.31 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.83 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $42.68 | 2019-2023 | |
| Lilly USA, LLC | $38.65 | 2022-2023 | Jardiance, Emgality |
| Sanofi-Aventis U.S. LLC | $32.89 | 2020-2022 | |
| Allergan, INC. | $29.99 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.98 | 2024-2025 | Xifaxan, Trulance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $27.71 | 2022 | |
| Alexion Pharmaceuticals, INC. | $27.40 | 2025 | Strensiq |
| Dexcom, INC. | $21.73 | 2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $16.24 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.91 | 2022 | |
| Travere Therapeutics, INC. | $3.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Agent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.